178 related articles for article (PubMed ID: 21996264)
1. The effects of 17β-estradiol and a selective estrogen receptor modulator, bazedoxifene, on ovarian carcinogenesis.
Romero IL; Lee W; Mitra AK; Gordon IO; Zhao Y; Leonhardt P; Penicka CV; Mui KL; Krausz TN; Greene GL; Lengyel E
Gynecol Oncol; 2012 Jan; 124(1):134-41. PubMed ID: 21996264
[TBL] [Abstract][Full Text] [Related]
2. Selective estrogen receptor modulators and the combination therapy conjugated estrogens/bazedoxifene: A review of effects on the breast.
Pickar JH; Komm BS
Post Reprod Health; 2015 Sep; 21(3):112-21. PubMed ID: 26289836
[TBL] [Abstract][Full Text] [Related]
3. Bazedoxifene - a promising brain active SERM that crosses the blood brain barrier and enhances spatial memory.
Hill RA; Kouremenos K; Tull D; Maggi A; Schroeder A; Gibbons A; Kulkarni J; Sundram S; Du X
Psychoneuroendocrinology; 2020 Nov; 121():104830. PubMed ID: 32858306
[TBL] [Abstract][Full Text] [Related]
4. Effects of oral contraceptives or a gonadotropin-releasing hormone agonist on ovarian carcinogenesis in genetically engineered mice.
Romero IL; Gordon IO; Jagadeeswaran S; Mui KL; Lee WS; Dinulescu DM; Krausz TN; Kim HH; Gilliam ML; Lengyel E
Cancer Prev Res (Phila); 2009 Sep; 2(9):792-9. PubMed ID: 19737983
[TBL] [Abstract][Full Text] [Related]
5. Bazedoxifene-induced vasodilation and inhibition of vasoconstriction is significantly greater than estradiol.
Zimmerman MA; Hutson DD; Mauvais-Jarvis F; Lindsey SH
Menopause; 2019 Feb; 26(2):172-181. PubMed ID: 30130290
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of GP130/STAT3 and EMT by combined bazedoxifene and paclitaxel treatment in ovarian cancer.
Park SA; Kim LK; Park HM; Kim HJ; Heo TH
Oncol Rep; 2022 Mar; 47(3):. PubMed ID: 35029286
[TBL] [Abstract][Full Text] [Related]
7. Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity.
Komm BS; Kharode YP; Bodine PV; Harris HA; Miller CP; Lyttle CR
Endocrinology; 2005 Sep; 146(9):3999-4008. PubMed ID: 15961563
[TBL] [Abstract][Full Text] [Related]
8. Repurposing the selective estrogen receptor modulator
Thilakasiri P; Huynh J; Poh AR; Tan CW; Nero TL; Tran K; Parslow AC; Afshar-Sterle S; Baloyan D; Hannan NJ; Buchert M; Scott AM; Griffin MD; Hollande F; Parker MW; Putoczki TL; Ernst M; Chand AL
EMBO Mol Med; 2019 Apr; 11(4):. PubMed ID: 30885958
[TBL] [Abstract][Full Text] [Related]
9. Effects of a tissue-selective estrogen complex on B lymphopoiesis and B cell function.
Nordqvist J; Bernardi A; Islander U; Carlsten H
Immunobiology; 2017 Aug; 222(8-9):918-923. PubMed ID: 28551078
[TBL] [Abstract][Full Text] [Related]
10. Differential biochemical and cellular actions of Premarin estrogens: distinct pharmacology of bazedoxifene-conjugated estrogens combination.
Berrodin TJ; Chang KC; Komm BS; Freedman LP; Nagpal S
Mol Endocrinol; 2009 Jan; 23(1):74-85. PubMed ID: 19036900
[TBL] [Abstract][Full Text] [Related]
11. Differential effects of selective estrogen receptor modulators on the vagina and its supportive tissues.
Liang R; Knight K; Nolfi A; Abramowitch S; Moalli PA
Menopause; 2016 Feb; 23(2):129-37. PubMed ID: 26382313
[TBL] [Abstract][Full Text] [Related]
12. Estrous cycle modulates ovarian carcinoma growth.
Armaiz-Pena GN; Mangala LS; Spannuth WA; Lin YG; Jennings NB; Nick AM; Langley RR; Schmandt R; Lutgendorf SK; Cole SW; Sood AK
Clin Cancer Res; 2009 May; 15(9):2971-8. PubMed ID: 19383821
[TBL] [Abstract][Full Text] [Related]
13. Pomegranate extract demonstrate a selective estrogen receptor modulator profile in human tumor cell lines and in vivo models of estrogen deprivation.
Sreeja S; Santhosh Kumar TR; Lakshmi BS; Sreeja S
J Nutr Biochem; 2012 Jul; 23(7):725-32. PubMed ID: 21839626
[TBL] [Abstract][Full Text] [Related]
14. Carcinogenicity and hormone studies with the tissue-selective estrogen receptor modulator bazadoxifene.
Wright DJ; Earnhardt JN; Perry R; Bailey S; Komm B; Minck DR; Cukierski MA
J Cell Physiol; 2013 Apr; 228(4):724-33. PubMed ID: 22949219
[TBL] [Abstract][Full Text] [Related]
15. Effects of the conjugated equine estrogen/bazedoxifene tissue-selective estrogen complex (TSEC) on mammary gland and breast cancer in mice.
Song Y; Santen RJ; Wang JP; Yue W
Endocrinology; 2012 Dec; 153(12):5706-15. PubMed ID: 23070546
[TBL] [Abstract][Full Text] [Related]
16. Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosis.
Pinkerton JV; Archer DF; Utian WH; Menegoci JC; Levine AB; Chines AA; Constantine GD
Menopause; 2009; 16(6):1102-8. PubMed ID: 19546825
[TBL] [Abstract][Full Text] [Related]
17. Proliferative lesions of ovarian granulosa cells and reversible hormonal changes induced in rats by a selective estrogen receptor modulator.
Long GG; Cohen IR; Gries CL; Young JK; Francis PC; Capen CC
Toxicol Pathol; 2001; 29(6):719-26. PubMed ID: 11794385
[TBL] [Abstract][Full Text] [Related]
18. Proliferative lesions of ovarian granulosa cells and reversible hormonal changes induced in rats by a selective estrogen receptor modulator.
Long GG; Cohen IR; Gries CL; Young JK; Francis PC; Capen CC
Toxicol Pathol; 2001; 29(4):403-10. PubMed ID: 11560244
[TBL] [Abstract][Full Text] [Related]
19. 17β-Estradiol sensitizes ovarian surface epithelium to transformation by suppressing Disabled-2 expression.
Vuong NH; Salah Salah O; Vanderhyden BC
Sci Rep; 2017 Dec; 7(1):16702. PubMed ID: 29196616
[TBL] [Abstract][Full Text] [Related]
20. Relaxant Effects of the Selective Estrogen Receptor Modulator, Bazedoxifene, and Estrogen Receptor Agonists in Isolated Rabbit Basilar Artery.
Castelló-Ruiz M; Salom JB; Fernández-Musoles R; Burguete MC; López-Morales MA; Arduini A; Jover-Mengual T; Hervás D; Torregrosa G; Alborch E
J Cardiovasc Pharmacol; 2016 Oct; 68(4):313-321. PubMed ID: 27389095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
